Press release - 18/02/2026 3D microtumors could revolutionize treatment decisions Chemotherapy is often a central component of treatment for advanced colorectal cancer. However, not every therapy is equally effective for every patient. Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* stem cell institute, and the biotech company Xilis in Utrecht, Netherlands, have now developed a new method for selecting the most effective drug before treatment begins. https://www.gesundheitsindustrie-bw.de/en/article/press-release/3d-microtumors-could-revolutionize-treatment-decisions
Press release - 12/03/2026 Brain Diseases: Certain Neurons Are Especially Susceptible to ALS and FTD Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms. Many patients have a common hallmark: A protein called TDP-43 clumps together in the neurons of the brain to form tiny lumps. Researchers at DZNE and Ulm University Hospital, together with international experts, have now discovered that these pathological changes primarily affect certain cells. https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-diseases-certain-neurons-are-especially-susceptible-als-and-ftd
Press release - 19/03/2026 New Approaches for Treatment-Resistant Disorders The German Center for Mental Health (DZPG) conducts nationwide research on individualized treatments for depression, anxiety disorders, and addiction. Its approach combines established therapeutic methods with innovative strategies to enhance overall treatment efficacy. The primary beneficiaries are patients for whom conventional therapies have so far proven insufficiently effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-treatment-resistant-disorders
Press release - 21/05/2026 Breakthrough in synthetic cell research Living systems such as cells rely on membrane pores and channels to transport molecules, exchange signals, and organize biochemical reactions. These functions emerge from dynamic interactions between molecular components. Researchers at the University of Stuttgart have used DNA nanotechnology to develop a synthetic membrane architecture that mimics such interactions. https://www.gesundheitsindustrie-bw.de/en/article/press-release/breakthrough-synthetic-cell-research
Press release - 18/11/2021 Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
Article - 09/10/2019 Epigenomics from the Cyber Valley Cyber Valley Stuttgart-Tübingen is a European hotspot for artificial intelligence and home to many renowned experts and scientists. They are now joined by Gabriele Schweikert, who heads up the Computational Epigenomics research group in the Cyber Valley’s Division of Computational Biology. Schweikert is interested in exploring epigenetic mechanisms using machine learning methods.https://www.gesundheitsindustrie-bw.de/en/article/news/epigenomik-aus-dem-cyber-valley
Article - 08/11/2019 Nanorobots as future minimally invasive tools for the eye It is difficult to place drugs in the right place in the eye. When using droplets, only a small fraction of the drug reaches its target. Injecting drugs into the eye is also more a matter of luck than judgement. Basic researchers at the Max Planck Institute for Intelligent Systems Stuttgart have developed a nanorobot that can be loaded with active ingredients for treating eye diseases and directed through the solid tissue of the vitreous body.https://www.gesundheitsindustrie-bw.de/en/article/news/Nanorobots-future-minimally-invasive-tools-for-eye
Press release - 06/02/2023 Fewer side effects thanks to personalised medicine Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.https://www.gesundheitsindustrie-bw.de/en/article/press-release/weniger-nebenwirkungen-dank-personalisierter-medizin
Press release - 09/07/2025 The evolution of cancer cells decoded Cancer can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Center have now developed a method that allows for the first time to reconstruct the temporal development—the evolution—of cancerous cells from a single tissue sample. https://www.gesundheitsindustrie-bw.de/en/article/press-release/evolution-cancer-cells-decoded
Press release - 11/08/2025 The Cerebral Cortex Ages Less than Thought The human brain ages less than thought and in layers – at least in the area of the cerebral cortex responsible for the sense of touch. Researchers at DZNE, the University of Magdeburg, and the Hertie Institute for Clinical Brain Research at the University of Tübingen come to this conclusion based on brain scans of young and older adults in addition to studies in mice. https://www.gesundheitsindustrie-bw.de/en/article/press-release/cerebral-cortex-ages-less-thought
Press release - 03/09/2025 Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors. https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-vaccination-against-hpv-related-tumors-nanoparticles-make-difference
Press release - 02/03/2026 Novel therapy for Phelan-McDermid syndrome Drug development to be funded with up to 1.7 million euros An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-therapy-phelan-mcdermid-syndrome-drug-development-be-funded-17-million-euros
Press release - 13/04/2026 SPT Labtech and EMBL GeneCore Collaborate to Advance Fully Walkaway Automation in Genomics Workflows SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and the European Molecular Biology Laboratory’s Genomics Core Facility (EMBL GeneCore), today announced a collaboration to advance fully walkaway automated genomics workflows. https://www.gesundheitsindustrie-bw.de/en/article/press-release/spt-labtech-and-embl-genecore-collaborate-advance-fully-walkaway-automation-genomics-workflows
Stem cell therapy for regenerating intervertebral discs - 16/07/2020 Ulm’s simulator has Europe’s back Back pain is often caused by intervertebral disc disorders. Much has already been tried and is available to help patients. Despite extensive progress, there is still no surefire recipe for success. iPSpine, an EU-funded project to which researchers from Ulm are contributing interdisciplinary engineering and biomedical expertise, aims to design a novel therapy for back pain based on intervertebral disc regeneration.https://www.gesundheitsindustrie-bw.de/en/article/news/Ulms-simulator-has-europes-back
Article - 04/11/2020 Rapid coronavirus test delivers results in 43 minutes The Hahn-Schickard Institute and Spindiag GmbH in Freiburg im Breisgau have joined forces to develop a rapid test used at the point of care. The test takes just 43 minutes to show whether a patient is infected with the coronavirus SARS-CoV-2. The rapid test is expected to be given market approval in Germany and the EU during the final quarter of 2020.https://www.gesundheitsindustrie-bw.de/en/article/news/rapid-coronavirus-test-delivers-results-43-minutes
Press release - 21/05/2025 How aging changes the blood system in humans and mice The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. The new discovery could help explain the chronic inflammation that occurs with age and makes us more susceptible to disease. It could also help identify early warning signs of unhealthy aging processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-aging-changes-blood-system-humans-and-mice
Phytopharmaceuticals - 14/09/2020 Medicinal cannabis to be grown in Germany Anyone who thinks hemp is just an inconspicuous plant, whose ingredients can be used, at best, as an intoxicant, can quickly be proven wrong. Besides being used as a valuable raw material for textiles and building materials, the plant has great potential as a medicinal drug. The CANNABIS-NET network, coordinated by the University of Hohenheim, has been set up to establish the basis for producing medicinal hemp in Germany.https://www.gesundheitsindustrie-bw.de/en/article/news/medicinal-cannabis-be-grown-germany
Press release - 16/06/2025 Novel laboratory models pave the way for targeted therapies for childhood sarcomas Sarcomas in soft tissue usually occur in young people and are difficult to treat. Due to a lack of laboratory models, the causes of their development are poorly understood. A team of researchers has now succeeded in creating mouse models with a functioning immune system that replicate sarcoma types that remain unstudied. The method opens up new avenues for the targeted development of immunotherapies for children and adolescents with sarcomas.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-laboratory-models-pave-way-targeted-therapies-childhood-sarcomas
Press release - 10/04/2026 Lancet Countdown Europe: New Report on Health and Climate Change Europe’s dependence on fossil fuels is not only making the continent economically and politically vulnerable, it also has consequences for the population’s health. Growing air pollution, heat damage and the climate-related spread of infectious diseases are looming, warns the 2026 Europe Report of the Lancet Countdown on Health and Climate Change, which its co-directors are about to present to the public. https://www.gesundheitsindustrie-bw.de/en/article/press-release/lancet-countdown-europe-new-report-health-and-climate-change
Article - 22/06/2021 Using virtual reality in the clinic to rehabilitate patients with cognitive disorders Outdated and inadequate methods of neurological rehabilitation are still being used for patients with neurological diseases or injuries – and what’s more, the treatment is usually too late. This is because cognitive training is especially important in the critical phases when the brain is particularly plastic. The Heidelberg-based company living brain proves that early treatment is possible using an extremely innovative method – with concentrated…https://www.gesundheitsindustrie-bw.de/en/article/news/using-virtual-reality-clinic-rehabilitate-patients-cognitive-disorders
Start-up Cerebri GmbH - 05/08/2024 Comprehensive EEG supply thanks to telemedicine Fewer and fewer patients are getting timely access to electroencephalograms, as the process of measuring brain activity and interpreting the results requires specific expertise. Cerebri GmbH, a newly established Tübingen-based company, aims to address this issue by offering user-friendly EEG caps and providing rapid, location-independent and top-tier diagnostics by experts.https://www.gesundheitsindustrie-bw.de/en/article/news/comprehensive-eeg-supply-thanks-telemedicine
Press release - 04/09/2024 Epigenetic changes reprogram astrocytes into brain stem cells With mice, researchers showed that experimentally induced lack of blood flow in the brain epigenetically reprograms astrocytes into brain stem cells, which in turn can give rise to nerve progenitor cells. This discovery shows that astrocytes could potentially be used in regenerative medicine to replace damaged nerve cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetic-changes-reprogram-astrocytes-brain-stem-cells
Baden-Württemberg AI Alliance - 08/04/2025 Achieving widespread use of AI Artificial intelligence presents both opportunities and risks. The Baden-Württemberg AI Alliance is dedicated to fostering collaboration among AI stakeholders to ensure that AI solutions deliver tangible benefits to citizens and businesses across the state. The alliance will also place greater emphasis on advancing AI applications within the healthcare sector.https://www.gesundheitsindustrie-bw.de/en/article/news/achieving-widespread-use-ai
Press release - 21/11/2025 Universität Heidelberg succeeds with three funding applications for Collaborative Research Centres Heidelberg University has been successful in the current approval round of the German Research Foundation (DFG) with three grant applications for major research consortia. In the life sciences and medicine, a Collaborative Research Centre working on the Wnt signaling pathway will enter its third funding period. Two transregional consortia with major participation by researchers from Ruperto Carola have also been extended. https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitat-heidelberg-succeeds-three-funding-applications-collaborative-research-centres
Press release - 18/12/2021 WHO publishes first classification of childhood tumors The International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO), will soon publish the first edition of its classification of childhood cancers. The new WHO classification forms the basis of modern, precise cancer diagnostics for physicians and pediatric oncologists worldwide and is based on the latest international research findings.https://www.gesundheitsindustrie-bw.de/en/article/press-release/who-publishes-first-classification-childhood-tumors
Press release - 11/09/2024 Researchers combine the power of artificial intelligence and the wiring diagram of a brain to predict brain cell activity Scientists have long sought ways to simulate the neural networks in the brain with computers in order to understand how it works. Now, researchers have combined new measurements of the wiring diagrams of the fruit fly with artificial intelligence methods to build a neural network that can do what few thought possible: To predict the activity of individual neurons without making a single measurement in a living brain. https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-combine-power-artificial-intelligence-and-wiring-diagram-brain-predict-brain-cell-activity
Advancing quantum technology into real-world applications - 06/11/2024 QSens: BMBF future cluster brings quantum sensors of the future into medicine The BMBF-funded future cluster ‘QSens – Quantum Sensors of the Future’ is developing ultra-sensitive sensors that could open up new options in medicine, enabling faster drug research, more accurate diagnostics and improved rehabilitation. The universities of Stuttgart and Ulm are actively working with 17 industry partners to put these cutting-edge innovations to immediate practical use.https://www.gesundheitsindustrie-bw.de/en/article/news/qsens-bmbf-future-cluster-brings-quantum-sensors-future-medicine
Press release - 23/01/2025 ERC Funding for „EmbryoNet-AI“ Konstanz biologist Patrick Müller receives a Proof of Concept Grant from the European Research Council for his project "EmbryoNet-AI". Its goal is the further development of an AI-supported platform for the automated evaluation of experiments – for example, in drug development.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-embryonet-ai